Dr Frédéric Pouliot speaks to ecancer at the 2020 ASCO GU meeting at San Francisco about the OSPREY study.
OSPREY is a PII/II study of PSMA-targeted PET/CT imaging in prostate cancer patients.
Dr Pouliot outlines the exciting results, and some more details of the study design.
He explains when these tracers may be in the clinic, the effectiveness, and also at what point of diagnosis they should be used.